Imago is poised to help clinicians identify abnormalities anywhere X-rays, ultrasound, CT, MRI, and other imaging modalities are used. The Company is focused initially on breast cancer screening and long-term monitoring of breast cancer treatment regimens.
Imago’s goal is to help radiologists improve the sensitivity and specificity of their readings. The Company’s multi-algorithmic approach can visualize abnormalities, malignant and benign, in even the densest breast tissue, which can lead to fewer false negatives.
Furthermore, Imago’s visualizations characterize all breast tissue. Consequently, objects that in the past might have appeared obscure, indistinct, or ill-defined might now be interpreted with greater accuracy after being processed by TN-1 than when viewing only the original mammogram. That, in turn, addresses many of the issues relative to false positive interpretations.
Altogether, these improved efficiencies hold the potential to help reduce the nearly $3B spent on over-diagnosis, lead to earlier identification of cancer (allowing for better treatment strategies), and reduce stress on women by reducing additional testing.
Imago’s technology extends beyond human medicine to visualize and characterize cancer in dogs and other animals. One out of every four dogs will be diagnosed with cancer, and the leading cause of cancer deaths for female dogs—just as it is for women—is breast cancer. Symptoms are often found too late for effective treatment strategies, and, as a result, half of affected pets will die within months.
To find cancers earlier, while they are potentially treatable, Imago is developing an automated software solution for screening and diagnostic assessment of images from multiple animal imaging modalities. The Company expects to also develop software products for large-animal veterinary practice, such as livestock, show and race horses, and exotic animals.
Imago’s software applies beyond medical specialties to include security, aerospace, and commercial vertical markets. Application examples include the ability to identify micro-fractures in welds, to see through corrosion for possible metal fatigue or failure, and even to characterizing and visualizing liquids and organic compounds.
There are potentially as many market opportunities as there are objects or conditions that can be captured as pixel data in images.
Imago was founded with a mission to deliver breakthrough visualization and characterization technology for post-processing of any grayscale image, including those used in medical, veterinary, and industrial applications. The Company has succeeded in developing a multi-algorithmic product that significantly improves the readability of content in a grayscale image, enabling professionals who rely on these images for critical decision-making to be able to “see beyond the limits of the human vision system.” Imago’s initial healthcare market focus is on visualization of abnormalities in screening mammograms, for which a clinical trial proposal is currently making its way through FDA review. Additionally, Imago is in development of a veterinary product which is expected to launch in late 2017. Other modalities and diseases within human healthcare, as well as product development for industrial applications, will follow.
For more information on Investment Opportunities and The Company, please contact us below...